# Anticoagulation Therapy Management

## Direct Oral Anticoagulants (DOACs)

### Apixaban (Eliquis)
- Dose: 5mg BID (reduce to 2.5mg BID if ≥2 of: age ≥80, weight ≤60kg, Cr ≥1.5)
- Renal: No dose adjustment for renal impairment; use with caution if CrCl <25
- No routine monitoring needed; Anti-Xa level if needed
- Reversal: Andexanet alfa (Andexxa)

### Rivaroxaban (Xarelto)
- AF dose: 20mg daily with evening meal (15mg daily if CrCl 15-50)
- VTE treatment: 15mg BID × 21 days, then 20mg daily
- Avoid if CrCl <15; take with food for optimal absorption
- Reversal: Andexanet alfa

### Dabigatran (Pradaxa)
- Dose: 150mg BID (110mg BID if CrCl 30-50 in some guidelines)
- Renal: Avoid if CrCl <30; highly renal-cleared
- Reversal: Idarucizumab (Praxbind) — specific reversal agent
- GI side effects common; take with food

### Edoxaban (Savaysa)
- Dose: 60mg daily (30mg daily if CrCl 15-50, weight ≤60kg, or P-gp inhibitors)
- Requires ≥5 days parenteral anticoagulation lead-in for VTE
- Avoid if CrCl >95 (reduced efficacy) or <15

## Warfarin Management
- **Target INR**: 2.0-3.0 for most indications (AF, VTE); 2.5-3.5 for mechanical mitral valve
- **Loading**: 5mg daily × 2-3 days, then adjust based on INR (avoid 10mg loading in elderly)
- **Monitoring**: INR 2-3x/week initially, then weekly, then every 4 weeks when stable
- **Drug interactions**: CYP2C9/VKORC1 substrates — amiodarone (decrease dose 30-50%), fluconazole, metronidazole, TMP-SMX increase INR; rifampin, carbamazepine, phenytoin decrease INR
- **Diet**: Consistent vitamin K intake; counsel on green leafy vegetables
- **Reversal**: Vitamin K (IV for urgent, PO for non-urgent), 4-factor PCC for life-threatening bleeding, FFP

## Bridging Therapy
- **High risk** (mechanical mitral valve, recent stroke <3 months, CHA2DS2-VASc ≥7): Bridge with LMWH
- **Low risk** (AF without recent stroke, CHA2DS2-VASc ≤4): No bridging (BRIDGE trial)
- **Moderate risk**: Individualize based on bleeding and thrombotic risk

## Perioperative Management
- **DOACs**: Hold 1-2 days for low bleeding risk procedures, 2-4 days for high bleeding risk; no bridging needed
- **Warfarin**: Stop 5 days before surgery; check INR day before; restart 12-24 hours post-op if hemostasis adequate

## Reversal Agents Summary
| Agent | Reversal |
|-------|----------|
| Warfarin | Vitamin K, 4-factor PCC, FFP |
| Dabigatran | Idarucizumab (Praxbind) |
| Apixaban/Rivaroxaban | Andexanet alfa; 4-factor PCC if unavailable |
| Heparin (UFH) | Protamine sulfate |
| Enoxaparin (LMWH) | Protamine (partial reversal ~60%) |
